Oral bioavailability of curcumin: problems and advancements

Liu, Weidong; Zhai, Yingjie; Heng, xueyuan; Yuan, Feng; Chen, Wenjun; Sun, Dezhong; Zhai, Guangxi

doi:10.3109/1061186x.2016.1157883

Cited by 434 publications

(291 citation statements)

References 70 publications

Supporting

Mentioning

285

Contrasting

Unclassified

Order By: Relevance

“…Second, the relatively high dose of curcuma used in our study induced moderate effects on serum hepcidin probably due to the low oral bioavailability of curcumin. Therefore, new formulations of curcuma with enhanced oral bioavailability should be tested in further studies . Third, one could argue that glucose was used as placebo in our study despite recent published data that showed links between glucose, insulin metabolism, and hepcidin .…”

Section: Discussionmentioning

confidence: 94%

Curcuma decreases serum hepcidin levels in healthy volunteers: a placebo‐controlled, randomized, double‐blind, cross‐over study

Lainé

Laviolle

Bardou-Jacquet

et al. 2017

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

Hepcidin, secreted by hepatocytes, controls iron metabolism by limiting iron egress in plasma. Hepcidin is upregulated during inflammation through the activation of the signal transducer and activator of transcription 3 (STAT3) transduction pathway, which decreases iron bioavailability and may explain the anemia of chronic inflammatory disease. In vitro, it has been shown that curcumin can decrease hepcidin synthesis by decreasing STAT3 activity. We conducted a proof-of-concept study to assess the effect of curcuma on hepcidin synthesis in human. This was a placebo-controlled, randomized, double-blind, cross-over, two-period study performed in 18 healthy male volunteers. Subjects received a single oral dose of 6 g curcuma containing 2% of curcumin or placebo. Serum hepcidin and iron parameters were assessed repeatedly until 48 h after dosing. When compared with a placebo curcuma decreased hepcidin levels significantly at 6 h (-19%, P = 0.004), 8 h (-17%, P = 0.009), and 12 h (-17%, P = 0.007) and tended to decrease hepcidin at 24 h (-15%, P = 0.076). Curcuma also significantly increased serum ferritin levels at 6 and 8 h (+7% for both times, P = 0.018, 0.030, respectively) and had no effects on serum iron, transferrin, and transferrin saturation. This pilot study showed that curcuma decreases serum hepcidin levels in human and supports the idea that curcuma could be useful in treating hepcidin overproduction during inflammatory processes. Confirmatory studies in patients with chronic inflammation are now required to determine the optimal dose and therapeutic scheme of curcuma.

show abstract

Section: Discussionmentioning

confidence: 94%

Curcuma decreases serum hepcidin levels in healthy volunteers: a placebo‐controlled, randomized, double‐blind, cross‐over study

Lainé

Laviolle

Bardou-Jacquet

et al. 2017

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…To overcome these problems several approaches are being developed like encapsulation of Cur in liposomes and polymeric micelles, formation of inclusion complexes and polymeric conjugates, and synthesis of new heterocyclic Cur derivatives and analogs (Liu et al, 2016). An efficacious solution to the bioavailability issue is needed to ensure appropriate tissue exposures of this natural product in clinical investigation.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Cardioprotective actions of curcumin on the pathogenic NFAT/COX-2/prostaglandin E2 pathway induced during Trypanosoma cruzi infection

2016

View full text Add to dashboard Cite

“…These physicochemical properties contribute to a low intestinal absorption and rapid metabolism of curcumin, thereby resulting in a low systemic bioavailability. While the biological activity of curcumin metabolites has been demonstrated, low plasma levels of parent compound is generally referred to as a main reason to explain the lack of complete translation of experimental findings on the anti‐tumor effects of curcumin to clinical practice (Kharat, Du, Zhang, & McClements, ; Liu et al, ).…”

Section: Introductionmentioning

confidence: 99%

Promising anti‐tumor properties of bisdemethoxycurcumin: A naturally occurring curcumin analogue

Ramezani

Hatamipour

Sahebkar

2017

Journal Cellular Physiology

View full text Add to dashboard Cite

Curcuminoids are turmeric-extracted phytochemicals with documented chemopreventive and anti-tumor activities against several types of malignancies. Curcuminoids can modulate several molecular pathways and cellular targets involved in different stages of tumor initiation, growth, and metastasis. Bisdemethoxycurcumin (BDMC) is a minor constituent (approximately 3%) of curcuminoids that has been shown to be more stable than the other two main curcuminoids, that is, curcumin and demthoxycurcumin. Recent studies have revealed that BDMC has anti-tumor effects exerted through a multimechanistic mode of action involving inhibition of cell proliferation, invasion and migration, metastasis and tumour growth, and induction of apoptotic death in cancer cells. The present review discusses the findings on the anti-tumor effects of BDMC, underlying mechanisms, and the relevance of finding for translational studies in human.

show abstract

Oral bioavailability of curcumin: problems and advancements

Cited by 434 publications

References 70 publications

Curcuma decreases serum hepcidin levels in healthy volunteers: a placebo‐controlled, randomized, double‐blind, cross‐over study

Curcuma decreases serum hepcidin levels in healthy volunteers: a placebo‐controlled, randomized, double‐blind, cross‐over study

Cardioprotective actions of curcumin on the pathogenic NFAT/COX-2/prostaglandin E2 pathway induced during Trypanosoma cruzi infection

Promising anti‐tumor properties of bisdemethoxycurcumin: A naturally occurring curcumin analogue

Contact Info

Product

Resources

About